Akari Therapeutics

DelveInsight's 2024 COVID-19 Pipeline Insight report details over 180 companies and 200+ pipeline drugs, covering clinical and nonclinical stages, therapeutic assessments, and inactive products. Highlights include Novavax's JN.1 subvariant vaccine and Gilead Sciences' obeldesivir trial. Promising therapies like DAS181 and Sarconeos are in advanced clinical trials.

The article discusses the importance of enabling JavaScript for optimal app performance.

Bullous pemphigoid (BP) affects elderly patients, often misdiagnosed, with no approved therapies in the US. Current treatments include off-label corticosteroids and immunomodulators. The BP pipeline includes advanced Phase III therapies like AstraZeneca’s Fasenra, Sanofi/Regeneron’s Dupixent, and Akari Therapeutics’ nomacopan. Unmet needs and market opportunities are significant due to lack of approved therapies and diagnostic biomarkers.